{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:55:26Z","timestamp":1776873326013,"version":"3.51.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,24]]},"DOI":"10.7759\/cureus.84722","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T09:15:36Z","timestamp":1748078136000},"source":"Crossref","is-referenced-by-count":2,"title":["Uterine Inflammatory Myofibroblastic Tumor Mimicking Myoma Treated With Gonadotropin-Releasing Hormone Therapy: A Case Report"],"prefix":"10.7759","author":[{"given":"Kenji","family":"Yorita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiko","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Inflammatory myofibroblastic tumor","author":"Parra-Herran C","year":"2020","unstructured":"Parra-Herran C, Lee CH, Bennett JA, Rabban JT. Inflammatory myofibroblastic tumor. WHO Classification of Tumours Series. International Agency for Research on Cancer, Lyon; 2020. 298-9."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000330","article-title":"Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course","volume":"39","author":"Parra-Herran C","year":"2015","unstructured":"Parra-Herran C, Quick CM, Howitt BE, Dal Cin P, Quade BJ, Nucci MR. Inflammatory myofibroblastic tumor of the uterus: clinical and pathologic review of 10 cases including a subset with aggressive clinical course. Am J Surg Pathol. 2015, 39:157-68. 10.1097\/PAS.0000000000000330","journal-title":"Am J Surg Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.69","article-title":"Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum","volume":"30","author":"Bennett JA","year":"2017","unstructured":"Bennett JA, Nardi V, Rouzbahman M, Morales-Oyarvide V, Nielsen GP, Oliva E. Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum. Mod Pathol. 2017, 30:1489-503. 10.1038\/modpathol.2017.69","journal-title":"Mod Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008974","article-title":"Uterine inflammatory myofibroblastic tumor: more common than expected: case report and review","volume":"96","author":"Mandato VD","year":"2017","unstructured":"Mandato VD, Valli R, Mastrofilippo V, Bisagni A, Aguzzoli L, La Sala GB. Uterine inflammatory myofibroblastic tumor: more common than expected: case report and review. Medicine (Baltimore). 2017, 96:e8974. 10.1097\/MD.0000000000008974","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02438-5","article-title":"Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report","volume":"19","author":"L\u00f3pez de Sa A","year":"2021","unstructured":"L\u00f3pez de Sa A, Pascual A, Garcia Santos J, et al.. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report. World J Surg Oncol. 2021, 19:331. 10.1186\/s12957-021-02438-5","journal-title":"World J Surg Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000909","article-title":"Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: a low threshold for ALK immunohistochemistry is required","volume":"41","author":"Pickett JL","year":"2017","unstructured":"Pickett JL, Chou A, Andrici JA, et al.. Inflammatory myofibroblastic tumors of the female genital tract are under-recognized: a low threshold for ALK immunohistochemistry is required. Am J Surg Pathol. 2017, 41:1433-42. 10.1097\/PAS.0000000000000909","journal-title":"Am J Surg Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0160-2","article-title":"STUMP un\"stumped\": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion","volume":"8","author":"Subbiah V","year":"2015","unstructured":"Subbiah V, McMahon C, Patel S, et al.. STUMP un\"stumped\": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol. 2015, 8:66. 10.1186\/s13045-015-0160-2","journal-title":"J Hematol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11604-021-01096-7","article-title":"MR imaging findings of unusual leiomyoma and malignant uterine myometrial tumors: what the radiologist should know","volume":"39","author":"Fujii S","year":"2021","unstructured":"Fujii S, Mukuda N, Ochiai R, et al.. MR imaging findings of unusual leiomyoma and malignant uterine myometrial tumors: what the radiologist should know. Jpn J Radiol. 2021, 39:527-39. 10.1007\/s11604-021-01096-7","journal-title":"Jpn J Radiol"},{"key":"ref9","article-title":"Magnetic resonance imaging-based prediction of uterine fibroid size reduction by relugolix using T2-weighted signal intensity ratio: a retrospective multicenter study","author":"Matsukawa J","year":"2025","unstructured":"Matsukawa J, Hiraka T, Sugiyama A, et al.. Magnetic resonance imaging-based prediction of uterine fibroid size reduction by relugolix using T2-weighted signal intensity ratio: a retrospective multicenter study. J Clin Gynecol Obstet. 2025,","journal-title":"J Clin Gynecol Obstet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000041310","article-title":"The clinicopathologic features of uterine inflammatory myofibroblastic tumor: a case report","volume":"104","author":"Pan X","year":"2025","unstructured":"Pan X, Zou J, Yang S, Wang Y, Luo J, Zhu X. The clinicopathologic features of uterine inflammatory myofibroblastic tumor: a case report. Medicine (Baltimore). 2025, 104:e41310. 10.1097\/MD.0000000000041310","journal-title":"Medicine (Baltimore)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001904","article-title":"Histopathologic and molecular characterization of uterine leiomyoma-like inflammatory myofibroblastic tumor: comparison to molecular subtypes of uterine leiomyoma","volume":"46","author":"Kuisma H","year":"2022","unstructured":"Kuisma H, Jokinen V, Pasanen A, et al.. Histopathologic and molecular characterization of uterine leiomyoma-like inflammatory myofibroblastic tumor: comparison to molecular subtypes of uterine leiomyoma. Am J Surg Pathol. 2022, 46:1126-36. 10.1097\/PAS.0000000000001904","journal-title":"Am J Surg Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000593","article-title":"Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms","volume":"40","author":"Parra-Herran C","year":"2016","unstructured":"Parra-Herran C, Schoolmeester JK, Yuan L, Dal Cin P, Fletcher CD, Quade BJ, Nucci MR. Myxoid leiomyosarcoma of the uterus: a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms. Am J Surg Pathol. 2016, 40:285-301. 10.1097\/PAS.0000000000000593","journal-title":"Am J Surg Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0046-8177(98)90116-2","article-title":"Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas","volume":"29","author":"Vu K","year":"1998","unstructured":"Vu K, Greenspan DL, Wu TC, Zacur HA, Kurman RJ. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol. 1998, 29:359-63. 10.1016\/s0046-8177(98)90116-2","journal-title":"Hum Pathol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xfss.2024.12.004","article-title":"Relugolix reduces leiomyoma extracellular matrix production via the transforming growth factor-beta pathway","volume":"6","author":"Schwartz A","year":"2025","unstructured":"Schwartz A, Malik M, Driggers P, Catherino WH. Relugolix reduces leiomyoma extracellular matrix production via the transforming growth factor-beta pathway. F S Sci. 2025, 6:213-20. 10.1016\/j.xfss.2024.12.004","journal-title":"F S Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373500-uterine-inflammatory-myofibroblastic-tumor-mimicking-myoma-treated-with-gonadotropin-releasing-hormone-therapy-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T09:15:37Z","timestamp":1748078137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373500-uterine-inflammatory-myofibroblastic-tumor-mimicking-myoma-treated-with-gonadotropin-releasing-hormone-therapy-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.84722","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}